U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07193966) titled 'NG2 and DLL3 CAR-T Cells Targeting Melanoma' on Sept. 12.
Brief Summary: The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Melanoma
Intervention:
BIOLOGICAL: NG2 and DLL3 CAR-T cells
Infusion of NG2 and DLL3-specific CAR-T via intravenous route
Recruitment Status: RECRUITING
Sponsor: Shenzhen Geno-Immune Medical Institute
Published by HT Digital Content Services with permission from Health Daily Digest....